ArticleJournal of the International AIDS Society2022

Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.

Anchalee Avihingsanon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.